Novavax, Inc. (BMV:NVAX)

Mexico flag Mexico · Delayed Price · Currency is MXN
146.15
+3.17 (2.22%)
At close: Aug 22, 2025, 2:00 PM CST
2.22%
Market Cap23.67B
Revenue (ttm)20.34B
Net Income (ttm)7.97B
Shares Outn/a
EPS (ttm)47.99
PE Ratio2.97
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume720
Average Volume1,166
Open148.44
Previous Close142.98
Day's Range146.15 - 149.70
52-Week Range106.50 - 294.00
Betan/a
RSI47.69
Earnings DateAug 8, 2025

About Novavax

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1987
Employees 952
Stock Exchange Mexican Stock Exchange
Ticker Symbol NVAX
Full Company Profile

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.